Fairvalue-Calculator Fairvalue-Calculator
EN DE

SofWave Medical Ltd (SOFWF) Fair Value & Analysis

Healthcare · US · Market cap $581M

Price$16.00
Fair Value$3.02
Upside-81.1%
Quality91/100
Evidence: High Range $2.27 – $3.78

Analysis

SofWave Medical Ltd (SOFWF) currently trades at $16.00, while our model-based Fair Value estimate is $3.02 — implying the stock looks roughly 81.1% overvalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

SofWave Medical Ltd. engages in the development, production, marketing, and distribution of non-invasive medical technology for skin firming and rejuvenation, tissue renewal, treatment of muscle, aging, and other physiological change in Israel, the United States, Europe, Southeast Asia, the Middle East, and internationally. The company offers an ultrasound technology that induces coagulation and subsequent revitalization for regenerated skin under the SUPERB brand; and non-invasive muscle toning technology under the Pure Impact VIP brand. It serves plastic surgeons, dermatologists, and other physicians who perform aesthetic treatments on patients. It also provides technical and clinical product support services. The company was incorporated in 2015 and is based in Yokneam Illit, Israel.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -83% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -81% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +19%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.